Chardan: 'We think CRSP's emergence as a credible player in the space could thus drive further valuation upside'
Tweet Send to a Friend
Chardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $82.00 price target on CRISPR Therapeutics (NASDAQ: CRSP)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
